Fidelity’s Feingold: 5 Investing Strategies for 2015
Jeffrey Feingold of Fidelity Magellan, a fund with 16% average annual returns over the past half-century, discusses his investing themes.
10 U.S. Companies With Lowest International Tax Rates
WalletHub recently released an analysis of taxes paid by the 100 largest firms and found S&P 100 companies pay about 22% less abroad.
Best 5 Investment Picks for 2013
One thing seems clear about the market's direction in 2013: Investors seeking yield–isn’t everybody nowadays–will find more joy in equities than in fixed income.
T. Rowe’s In-House Doctor Gives Healthcare Stock Picks for 2013
T. Rowe Price’s doctor is in–and diagnosing where the best stock picks can be found in the healthcare sector as reforms take hold next year.
Top Performing Sector ETFs of 2011
Sectors, dividends and ETFs could be the new gold, frankincense and myrrh based on performance over the past year.
Thanks to new drugs, acquisitions and other factors, biotech and health-care firms alike are forging beneficial growth and development strategies - which is good news...
Blending In Nicely
Large-cap blend funds seek to combine the best of both worlds--growth-oriented stocks which provide high earnings growth, tempered by value-oriented issues which offer the stability...
A Time of Innovation
New products and other factors drive growth in health care/biotech, despite a cautious regulatory environment, analysts say. ----- Jason Kantor RBC Capital Markets 415-633-8565 Jason.firstname.lastname@example.org Outlook: Fundamentally, I don't think the...
Interview: Tony Weber and Chuck McCurdy of ABN AMRO Veredus Select Growth Fund
S&P Rank: 5 Stars Using Inefficiency to Their Advantage
Evan McCulloch of Franklin Biotechnology Discovery Fund
S&P Rank: 3 Stars March 11, 2004 Biotechs High on Drug Approvals